Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InNexus Biotechnology, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology, has appointed David Warden to its board of directors.
Subscribe to our email newsletter
Mr Warden was a founding partner of Yetter, Warden & Coleman. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to antitrust, securities violations, trade secrets, patents, and other business and technology litigation.
Jeff Morhet, chairman and CEO of InNexus Biotechnology, said: “I am pleased to have David join our team as a director on our board. His broad legal experience and, in particular, his expertise in patent law will prove valuable as we continue to expand and fortify our intellectual property position.”